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Gastric cancer (GC) is one of the leading causes of cancer‐related death worldwide, especially in Japan,[1](#ijc29916-bib-0001){ref-type="ref"} and is a major clinical problem that severely impairs the patient\'s quality of life and usually leads to death. Elucidation of the mechanisms mediating gastric carcinogenesis is expected to facilitate improved outcomes in patients with invasive cancer and to improve the patient\'s quality of life by detection of tumors or precancerous lesions as early as possible, leading to more effective treatment.

Previous studies have shown that there are two classical molecular pathways involved in the pathogenesis of colorectal cancers (CRCs) and GCs: microsatellite instability (MSI) and chromosomal instability \[CIN, similar to the microsatellite stable (MSS) status\].[2](#ijc29916-bib-0002){ref-type="ref"}, [3](#ijc29916-bib-0003){ref-type="ref"}, [4](#ijc29916-bib-0004){ref-type="ref"}, [5](#ijc29916-bib-0005){ref-type="ref"}, [6](#ijc29916-bib-0006){ref-type="ref"} CRCs with the MSI phenotype (MSI‐high tumors) are characterized by mutations in the *KRAS* or *BRAF* gene, genome‐wide hypermethylation, DNA diploidy and distinct clinicopathological features, such as older age, female gender, location in the proximal colon and histology of mucinous or medullary carcinoma.[2](#ijc29916-bib-0002){ref-type="ref"}, [3](#ijc29916-bib-0003){ref-type="ref"}, [4](#ijc29916-bib-0004){ref-type="ref"} However, CIN (MSS) is closely associated with an accumulation of multiple cancer‐related genes exhibiting loss of heterozygosity, as well as mutations in *p53* and DNA aneuploidy.[2](#ijc29916-bib-0002){ref-type="ref"}, [3](#ijc29916-bib-0003){ref-type="ref"}, [4](#ijc29916-bib-0004){ref-type="ref"} The CpG island methylation phenotype (CIMP), characterized by extensive hypermethylation of multiple CpG islands within the genome, is currently recognized as one of the major mechanisms in colorectal and gastric carcinogenesis.[7](#ijc29916-bib-0007){ref-type="ref"}, [8](#ijc29916-bib-0008){ref-type="ref"} Although the CIMP status has been classified into high, low and negative, CIMP‐high CRCs also have distinct clinicopathological and molecular profiles, such as older age, female gender, location in the proximal tumor, poorly differentiated or mucinous histology and high rates of MSI and *BRAF* mutations as compared with CIMP‐low/negative CRCs.[3](#ijc29916-bib-0003){ref-type="ref"}, [4](#ijc29916-bib-0004){ref-type="ref"}, [5](#ijc29916-bib-0005){ref-type="ref"} Most of these clinicopathological and molecular features in CIMP‐high CRCs overlap with sporadic GCs having the MSI phenotype.[9](#ijc29916-bib-0009){ref-type="ref"}, [10](#ijc29916-bib-0010){ref-type="ref"}, [11](#ijc29916-bib-0011){ref-type="ref"} However, it is unclear whether these overlapping clinicopathological and molecular features of CRCs also apply to GCs.

Previous studies have shown that MSI is found in 15--39% of sporadic GCs. GC with the MSI‐high phenotype is characterized by old age, antral location, differentiated type, mucinous or medullary histological patterns and reduced lymph node metastasis.[12](#ijc29916-bib-0012){ref-type="ref"}, [13](#ijc29916-bib-0013){ref-type="ref"} Although MSI is caused by gremlin mutations in mismatch repair genes (*MLH‐1* and *MSH2*) in hereditary nonpolyposis colorectal cancer, MSI is closely associated with methylation of the *MLH‐1* gene in sporadic GCs.[12](#ijc29916-bib-0012){ref-type="ref"} Leung *et al*. showed that hypermethylation of the CpG island in the *MLH‐1* promoter region was present in 100% of the sporadic MSI‐high GCs examined in their study.[12](#ijc29916-bib-0012){ref-type="ref"} In addition, they also showed that there is a close association between *MLH‐1* gene methylation and loss of MLH‐1 expression (90% of cases).[12](#ijc29916-bib-0012){ref-type="ref"}, [14](#ijc29916-bib-0014){ref-type="ref"} Methylation of the *MLH‐1* gene has been shown to cause transcriptional silencing of some important genes, including *p16*, *RUNX3* and *E‐cadherin*, suggesting that such tumors exhibit the CIMP phenotype.[12](#ijc29916-bib-0012){ref-type="ref"}, [14](#ijc29916-bib-0014){ref-type="ref"} Recent studies have shown that serrated lesions \[in particular, sessile serrated adenoma/polyp (SSA/P)\] are considered early precursor lesions of MSI‐high CRC. This pathway is characterized by distinct pathological and molecular profiles that differ from those of traditional adenoma.[15](#ijc29916-bib-0015){ref-type="ref"}, [16](#ijc29916-bib-0016){ref-type="ref"} SSA/P is thought to develop into cancer through the sequence of hyperplastic polyp--SSA/P--dysplasia--MSI‐high cancer.[15](#ijc29916-bib-0015){ref-type="ref"}, [16](#ijc29916-bib-0016){ref-type="ref"} Although serrated lesions have been recognized as precursors of MSI‐high CRCs, the clinicopathological and molecular profiles of precursor lesions in MSI‐high GCs have not been fully elucidated.

A limited number of previous studies have examined the clinicopathological and molecular findings of early GCs (EGCs) according to the MSI phenotype; most studies have focused on advanced GCs.[17](#ijc29916-bib-0017){ref-type="ref"}, [18](#ijc29916-bib-0018){ref-type="ref"} In addition, the clinicopathological features of patients with EGCs having the MSI phenotype and the molecular alterations acquired in EGCs having the MSI phenotype are still unclear. Thus, the aims of this study were to elucidate the clinicopathological and molecular features of EGCs having the MSI phenotype (MSI‐high EGC) and to compare the findings with the clinicopathological and molecular features of MSS or MSI‐low EGCs.

Material and Methods {#ijc29916-sec-0002}
====================

Patients {#ijc29916-sec-0003}
--------

We selected 330 intestinal‐type sporadic EGCs obtained from Iwate Medical University Hospital. EGCs were defined as tumors that may have invaded into the submucosa, but were confined within the submucosa, irrespective of the presence of lymph node metastases. In this study, patients with Lynch syndrome were excluded. Most of the examined EGCs were confined to the mucosa (intramucosal cancer). Tumor location and invasion were classified according to the classification of the Japanese Gastric Cancer Association.[19](#ijc29916-bib-0019){ref-type="ref"} Tumors were classified as well‐differentiated adenocarcinoma, moderately differentiated adenocarcinoma, papillary adenocarcinoma, or mixed adenocarcinoma by histological analysis according to the modified classification of the Japanese Gastric Cancer Association. Papillary adenocarcinomas were defined as tumors having a papillary component. If characteristics of both tubular and papillary adenocarcinoma were present within the same tumor, the tumor was classified as mixed adenocarcinoma. Finally, patients with Epstein‐Barr virus‐associated EGC were not included in this study. The local ethics committees of Iwate Medical University approved the sample collection and study design and written informed consent was obtained from all patients.

Three hundred thirty matched paired gastric cancer and non‐neoplastic gastric tissues were sampled. Tissues for clinicopathological analysis were obtained from a region of the resected stomach mucosa adjacent to the region used for genetic analysis. Hematoxylin and eosin sections of the representative tissue were examined to characterize tumor features and to evaluate the percentage of tumor cells. All samples contained at least 50% tumor cells. Non‐neoplastic tissues adjacent normal tissues were isolated from a region that was a minimum of 0.5--2 cm from the primary tumor lesion.

DNA extraction {#ijc29916-sec-0004}
--------------

Samples were directly snap‐frozen and stored at −80°C. DNA was extracted from normal and tumor tissues by sodium dodecyl sulfate lysis and proteinase K digestion, followed by a phenol‐chloroform procedure, as reported previously.[20](#ijc29916-bib-0020){ref-type="ref"}

Immunohistochemical analysis {#ijc29916-sec-0005}
----------------------------

Sections (4 μm thick) from formalin‐fixed and paraffin‐embedded tissue blocks were analyzed using an extensive panel of immunohistochemical markers, including p53 (DO7, DAKO, Copenhagen, Denmark), MUC2 (Novocastra Laboratories, Newcastle, UK), MUC5AC (Novocastra Laboratories), MUC6 (Novocastra Laboratories), CD10 (Novocastra Laboratories) and MLH‐1 (BD Pharmingen). This immunohistochemical panel covers the markers used for evaluating gastric tumorigenesis, as described previously.[20](#ijc29916-bib-0020){ref-type="ref"} Non‐neoplastic gastric mucosa served as a control for p53, MUC2, MUC5AC, MUC6, cdx2 and MLH‐1 staining. Only nuclear staining of p53 product was measured as positive. Overexpression of p53 was defined as positive expression in \[mt\]30% of cells. However, if \[mt\]10% of the tumor cells were immunopositive for MUC2, MUC5AC, MUC6 or CD10, tumors were considered positive for the corresponding protein. If \[mt\]30% of the tumor cells showed loss of expression or reduced expression of MLH‐1, the tumor was regarded as MLH‐1 negative. All immunohistochemical stains were used daily in our laboratory, and negative controls were carried out routinely using the Dako Envision system (Dako, Denmark) according to the manufacturer\'s instructions.

Methylation analysis and pyrosequencing for evaluation of *KRAS* and *BRAF* mutations {#ijc29916-sec-0006}
-------------------------------------------------------------------------------------

Pyrosequencing targeted at *KRAS* (codons 12 and 13) and *BRAF* (codon 600) was performed using a PyroMark Q24 instrument (Qiagen, Venlo, The Netherlands) according to the manufacturer\'s instructions.[21](#ijc29916-bib-0021){ref-type="ref"}, [22](#ijc29916-bib-0022){ref-type="ref"} Briefly, the polymerase chain reaction (PCR) product (25 μL) was bound to streptavidin Sepharose HP (GE Healthcare, Brøndby, Denmark), purified, washed, denatured in 0.2 M NaOH and washed again. Before pyrosequencing, 0.3 μM sequencing primer was annealed to the purified single‐stranded PCR product by heating to 80°C for 2 min.

Methylation analysis and pyrosequencing for evaluation of methylation {#ijc29916-sec-0007}
---------------------------------------------------------------------

The DNA methylation status of each gene promoter region was established by PCR analysis of bisulfite‐modified genomic DNA (EpiTect Bisulfite Kit; Qiagen) using pyrosequencing for quantitative methylation analysis (Pyromark Q24; Qiagen NV). The primers were designed using the Pyromark Assay Designing Software package (Qiagen NV), with 3--4 CpG sites included for analysis of promoter methylation. The primers used for analysis of *KRAS* and *BRAF* mutations are described elsewhere (the primers for methylation analysis were designed and are not indicated in this study).[21](#ijc29916-bib-0021){ref-type="ref"}, [22](#ijc29916-bib-0022){ref-type="ref"}

We quantified DNA methylation in 6 specific promoters originally described by Yagi and colleagues.[23](#ijc29916-bib-0023){ref-type="ref"}, [24](#ijc29916-bib-0024){ref-type="ref"} Briefly, after methylation analysis of a panel of 3 markers (*RUNX3*, *MINT31* and *LOX*), high methylation epigenotype (HME) tumors were defined as those with at least 2 methylated markers. The remaining tumors were screened using 3 markers (*NEUROG1*, *ELMO1* and *THBD*); intermediate methylation epigenotype (IME) tumors were defined as those with at least 2 methylated markers. Tumors not classified as HME or IME were designated as low methylation epigenotype (LME). In addition, methylation of *MLH‐1* was also quantified.

The cut‐off value for the mutation assay was 15% mutant alleles, while that for the methylation assay was 30% of tumor cells.

Analysis of allelic imbalance (AI) by PCR {#ijc29916-sec-0008}
-----------------------------------------

Allelic losses on chromosomes 1p, 3p, 4p, 5q, 8p, 9p, 13q, 17p, 18p and 22q were examined in paired tumor and normal DNA samples obtained from 330 patients with EGC using 22 highly pleomorphic microsatellite markers (D1S228, D1S548, D3S2402, D3S1234, D4S2639, D4S1601, D5S107, D5S346, D5S299, D5S82, D8S201, D8S513, D8S532, D9S171, D9S1118, D13S162, TP53, D18S487, D18S34, D22S274, D22S1140 and D22S1168). These microsatellite markers have been reported frequently in GCs and CRCs. In addition, a variable number of tandem repeat polymorphisms at the DCC locus were tested. Microsatellite sequences were obtained from specific primers reported in the Genome Database (<http://gdbwww.gdb.org/gdb>/). PCR and microsatellite analysis for those markers were performed as previously described.[20](#ijc29916-bib-0020){ref-type="ref"}

Determination of AI {#ijc29916-sec-0009}
-------------------

The peaks produced by the normal DNA sample were used to determine whether the cancerous sample was homozygous (one peak) or heterozygous (two peaks). The allelic ratio was calculated as previously described.[25](#ijc29916-bib-0025){ref-type="ref"} A tumor was considered to have AI if the allele peak ratio was ≤0.70, representing an allelic signal reduction of at least 30%. Samples were regarded as uninformative if they showed constitutional homozygosity or MSI. When **AI**s were observed in at least one locus, the imbalances of those loci were confirmed. The data were collected automatically and analyzed using GeneScan software (Applied Biosystems, CA) to determine the allele score and to assess the possibility of allelic loss.

Scoring of AI {#ijc29916-sec-0010}
-------------

AI status was scored according to the following criteria. A tumor sample was considered to be AI‐high if \[mt\]60% of the loci showed AI. When \<30% of the loci showed AI, the tumor was designated as AI‐low. A tumor was regarded as AI‐intermediate if between 30 and 60% of loci had AI.

Analysis of MSI {#ijc29916-sec-0011}
---------------

Three dinucleotide repeat markers (D2S123, D5S346 and D17S250) and two adenine mononucleotide repeats (BAT25 and BAT26) were used to determine the presence of tumor MSI.[26](#ijc29916-bib-0026){ref-type="ref"} Tumors were considered positive for MSI when a novel, abnormally sized band was present in the tumor sample as compared to the corresponding normal DNA sample. Tumors were classified as having a high level of MSI (MSI‐H) if 2 or more markers had allelic shifts, having a low level of MSI (MSI‐L) if only 1 of the 5 markers had an allelic shift, or MSS when no markers had an allelic shift.

Statistical analysis {#ijc29916-sec-0012}
--------------------

Data obtained for histological features, immunohistochemical findings, AI of chromosomal loci, methylation status and *MLH‐1* methylation based on MSI‐status were analyzed using the Kruskal‐Wallis H test with the aid of Stat Mate‐III software (Atom, Tokyo, Japan). If significant differences were found among the four groups, differences between two groups were analyzed using *χ* ^2^ tests (Stat Mate‐III software). Statistical analysis of *MLH‐1* methylation and loss or reduction of MLH‐1 expression was carried out using *χ* ^2^ tests (Stat Mate‐III software) for comparisons between the two groups. Differences with *p* values of \<0.05 were considered significant.

Results {#ijc29916-sec-0013}
=======

Clinicopathological findings in patient subgroups classified according to MSI status {#ijc29916-sec-0014}
------------------------------------------------------------------------------------

Forty‐five GC cases (13.6%) exhibited the MSI‐H phenotype, 9 cases (2.7%) exhibited the MSI‐L phenotype and the remaining 276 cases (83.6%) exhibited the MSS phenotype. Clinicopathological findings based on MSI status are shown in Table [1](#ijc29916-tbl-0001){ref-type="table-wrap"}. Significant associations with the MSI‐H phenotype were found in patients with older age (*p* \< 0.001), papillary adenocarcinoma (*p* \< 0.01) and mixed adenocarcinoma (*p* \< 0.001).

###### 

Clinicopathological findings of early gastric cancer according to MSI status

                         Total (%)    MSI high (%)   MSI low (%)   MSS (%)      p Values
  ---------------------- ------------ -------------- ------------- ------------ ----------
  Total                  330          45 (13.6)      9 (2.7)       276 (83.6)   
  Male/Female            244/86       32/13          5/4           207/69       
  Mean age (years)       71.9         74.5           68.3          71.6         0.001
  (Range)                (45--91)     (50--91)       (45--87)      (45--89)     
  Location                                                                      
  U                      56 (17.0)    7 (15.6)       3 (33.3)      46 (16.7)    
  M                      127 (38.5)   16 (35.6)      4 (44.4)      107 (38.8)   
  L                      147 (44.5)   22 (48.8)      2 (22.3)      123 (44.5)   N.S
  Macroscopic findings                                                          
  IIa                    190 (57.6)   28 (62.2)      6 (66.7)      156 (56.5)   
  IIc                    105 (31.8)   12 (26.7)      2 (22.2)      91(33.0)     
  Mixed                  30 (9.1)     4 (8.9)        1(11.1)       25 (9.1)     
  IIb                    5(1.5)       1(2.2)         0(0)          4 (1.4)      N.S
  Histological type                                                             
  tub1                   261(79.1)    29 (64.4)      6 (66.7)      226 (81.9)   
  tub2                   51(15.5)     7 (15.6)       3 (22.3)      41(14.9)     
  Pap                    18 (5.4)     9 (20.0)       0(0)          9 (3.2)      0.01
  MA                     48 (14.5)    22 (48.9)      2 (22.8)      24 (8.7)     0.001
  Lymphatic invasion                                                            
  Presence               41(12.4)     8 (17.8)       0(0)          33 (12.0)    
  Absence                289 (87.6)   37 (82.2)      9(100)        243 (88.0)   N.S
  Venous invasion                                                               
  Presence               8 (2.4)      0(0)           3 (33.3)      5 (1.8)      
  Absence                322 (97.6)   45 (100)       6 (66.7)      271(98.2)    N.S
  Multiple cancer                                                               
  Presence               55 (16.7)    6 (13.3)       0(0)          49 (17.8)    
  Absence                275 (83.3)   39 (86.7)      9 (100)       227 (82.2)   N.S

Immunohistochemical findings in patient subgroups based on MSI status {#ijc29916-sec-0015}
---------------------------------------------------------------------

Immunohistochemical findings in samples of EGCs having the MSI‐H, MSI‐L and MSS phenotypes are depicted in Figure [1](#ijc29916-fig-0001){ref-type="fig"}. The gastric mucin markers MUC5AC and MUC6 exhibited significantly elevated expression in MSI‐H EGCs compared to those in MSS EGCs (*p* \< 0.001 for MUC5AC and *p* \< 0.001 for MUC6). The expression of CD10 was significantly more frequent in MSI‐H EGCs (2/16, 11%) than in MSS EGCs (*p* \< 0.001). p53 overexpression and MUC2 expression were not associated with the MSI status of EGCs. The frequency of MLH‐1 expression in EGCs with the MSI‐H phenotype was significantly higher than that in EGCs with the MSI‐L and MSS phenotypes (*p* \< 0.001 and *p* \< 0.01, respectively).

![Frequencies of immunohistochemical expression of various targets in early gastric cancers according to MSI status. \[Color figure can be viewed in the online issue, which is available at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).\]](IJC-138-1689-g001){#ijc29916-fig-0001}

Association of methylation status with MSI status {#ijc29916-sec-0016}
-------------------------------------------------

The association between CIMP status in MSI‐H, MSI‐L and MSS EGCs is shown in Figure [2](#ijc29916-fig-0002){ref-type="fig"}. Although there was a significant difference in HME between MSI‐H and MSS EGCs (*p* \< 0.001), the frequency of LME was significantly higher for MSS EGCs than for MSI‐H EGCs (*p* \< 0.001). The frequency of IME was significantly higher in MSS EGCs than in MSI‐H EGCs (*p* \< 0.001).

![Frequencies of methylation status in early gastric cancers based on methylation status. \[Color figure can be viewed in the online issue, which is available at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).\]](IJC-138-1689-g002){#ijc29916-fig-0002}

Relationship of *MLH‐1* methylation with loss or reduction of MLH‐1 expression based on MSI status {#ijc29916-sec-0017}
--------------------------------------------------------------------------------------------------

The frequency of methylation of the *MLH‐1* gene was significantly higher in EGCs with the MSI‐H phenotype (34/45, 75.6%) than in EGCs with the MSI‐L (0/9) or MSS (0/276) phenotype (*p* \< 0.001 and *p* \< 0.01, respectively). Methylation of the *MLH‐1* gene (34 cases) was significantly associated with loss or reduction of MLH‐1 expression in EGCs with the MSI‐H phenotype (30/34 cases; *p* \< 0.05). However, although the *MLH*‐*1* gene was methylated in EGCs with the MSI phenotype, MLH‐1 protein was expressed in four EGCs with the MSI‐H phenotype. Conversely, loss or reduction of MLH‐1 protein levels was found in six EGCs with the MSI‐H phenotype. No methylation of *MLH‐1* was observed in EGCs having the MSI‐L phenotype. However, only one tumor without *MLH‐1* methylation was observed in EGCs having the MSI‐L phenotype. Although no methylation of the *MLH‐1* gene was detected in MSS EGCs, loss or reduction of MLH‐1 protein expression was observed in 15 EGCs having the MSS phenotype.

Association between AI in cancer‐related chromosomal loci and MSI status {#ijc29916-sec-0018}
------------------------------------------------------------------------

The AIs present at each chromosome location are shown in Figure [3](#ijc29916-fig-0003){ref-type="fig"}. The number of chromosome arms harboring AIs varied among individuals. Interestingly, the incidence of AI in chromosomes 3p and 22q was significantly elevated in EGCs with the MSI‐H phenotype compared with EGCs with the MSS phenotype (*p* \< 0.01). Although AIs in chromosomes 1p, 4p, 5q, 8p, 9p, 13q, 17p and 18q were more frequent in EGCs with the MSI‐H phenotype than in EGCs with the MSI‐L and MSS phenotypes, the differences were not statistically significant.

![Frequencies of **AI** at cancer‐related loci in early gastric cancer based on MSI status. \[Color figure can be viewed in the online issue, which is available at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).\]](IJC-138-1689-g003){#ijc29916-fig-0003}

The frequency of AI‐high status in MSI‐L and MSS‐EGCs was significantly higher than that in MSI‐H EGCs (*p* \< 0.001). Additionally, the frequencies of AI‐intermediate status in EGCs with the MSI‐L and MSS phenotypes were significantly different from that in EGCs with the MSI‐H phenotype (*p* \< 0.001 for both). Significant differences in the frequencies of AI‐low status were observed between EGCs with the MSI‐H phenotype and EGCs with the MSI‐L or MSS phenotype (*p* \< 0.001 for both). These associations are depicted in Figure [4](#ijc29916-fig-0004){ref-type="fig"}.

![AI status in early gastric cancer based on MSI status. \[Color figure can be viewed in the online issue, which is available at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).\]](IJC-138-1689-g004){#ijc29916-fig-0004}

Analysis of *KRAS* and *BRAF* mutations in EGCs with different MSI statuses {#ijc29916-sec-0019}
---------------------------------------------------------------------------

As shown in Figure [5](#ijc29916-fig-0005){ref-type="fig"}, we next examined mutations in the *KRAS* and *BRAF* genes in 156 EGC specimens (MSI‐H, *n* = 45; MSI‐L, *n* = 9; MSS, *n* = 102). Mutation in *KRAS* (codons 12, 13 and 61) was identified in 2 of 45 EGCs with the MSI‐H phenotype and 5 of 102 EGCs with the MSS phenotype. However, no mutations in *BRAF* (V600E mutation) were detected in all EGCs.

![Representative case of early gastric cancer with the MSI phenotype. (*a*) Histological features of early gastric cancers with the MSI‐high phenotype. Papillary features were observed. (*b*). Positive immunostaining of MUC5AC. (*c*) Positive immunostaining for MUC6. (*d*) Negative immunostaining for MUC2. (*e*) Negative immunostaining for CD10. (*f*) Overexpression for p53. (*g*) Negative immunostaining for MLH‐1. (*h*) Analysis of methylation status. The methylation status was classified as having a high methylation epigenotype pattern. (*i*) Analysis of **AI**. A 5q **AI** was detected. MSI was found at 8q and 17p. (*j*) MSI analysis. Additional changes were observed. (*k*) Analysis of mutations in *KRAS* and *BRAF*. No mutations were found.](IJC-138-1689-g005){#ijc29916-fig-0005}

Discussion {#ijc29916-sec-0020}
==========

The advantage of diagnostic pathology is that it can detect the histological or molecular characteristics of early‐stages tumors, potentially providing histological or molecular predictions of MSI at the time of diagnosis. This concept is strongly supported by the observation that MSI‐H tumors exhibit distinct tumor histology and molecular events.[27](#ijc29916-bib-0027){ref-type="ref"}, [28](#ijc29916-bib-0028){ref-type="ref"} In this study, we examined genetic and epigenetic pathways and markers for EGC, with the goal of preferential identifying pathways specific to EGC based on MSI status. Previous studies have shown that GCs generally exhibit high levels of MSI; however, large sample sizes were needed to reach these conclusions.[29](#ijc29916-bib-0029){ref-type="ref"}, [30](#ijc29916-bib-0030){ref-type="ref"} In this study, we found an MSI rate of 13.6% in 330 EGC samples from Japanese patients; this rate is consistent with those presented in previous reports.[12](#ijc29916-bib-0012){ref-type="ref"}, [30](#ijc29916-bib-0030){ref-type="ref"}, [31](#ijc29916-bib-0031){ref-type="ref"}, [32](#ijc29916-bib-0032){ref-type="ref"}

Previous studies have shown that GCs having the MSI phenotype exhibit distinct clinicopathological features, such as association with distal tumor location, older age at onset and distinct histology of mucinous and medullary carcinomas.[27](#ijc29916-bib-0027){ref-type="ref"}, [28](#ijc29916-bib-0028){ref-type="ref"} However, little is known regarding the clinicopathological features of EGCs with the MSI phenotype. One of the histological features of MSI‐H tumors is the presence of morphological heterogeneity, as defined by the finding of 2 or more distinct subhistological types distinguished on the basis of grade of differentiation (for example, moderate to poor) or histological type (for example, differentiated type, papillary adenocarcinoma, medullary carcinoma and mucinous).[28](#ijc29916-bib-0028){ref-type="ref"}, [29](#ijc29916-bib-0029){ref-type="ref"} However, the heterogeneity of MSI‐H cancer is unique to advanced‐stage disease. In this study, we found a close association between EGCs with the MSI phenotype and papillary adenocarcinoma or mixed histological type with tubular and papillary components. It is important for diagnostic pathologists to identify the specific histological features of MSI‐high EGC given that MSI‐high cancer shows rapid progression in both GC and CRC.[8](#ijc29916-bib-0008){ref-type="ref"}, [12](#ijc29916-bib-0012){ref-type="ref"} Furthermore, recent evidence has suggested that patients with CRC and GC manifesting MSI have different prognoses and responses to chemotherapeutic agents.[8](#ijc29916-bib-0008){ref-type="ref"}, [12](#ijc29916-bib-0012){ref-type="ref"} Therefore, early detection of GC with the MSI‐phenotype may be helpful for gastroenterologists. We suggest that papillary adenocarcinoma or mixed cancer of tubular and papillary components may be a novel marker for early prediction of the MSI‐H status in GCs.

High frequencies of the gastric mucins MUC5AC and/or MUC6 have been previously reported in MSI‐H tumors,[30](#ijc29916-bib-0030){ref-type="ref"} including MSI‐H GCs. A recent study showed that hypomethylation of the promoter regions of the *MUC5AC* and *MUC6* genes is closely associated with MSI‐H status in CRC.[31](#ijc29916-bib-0031){ref-type="ref"} Moreover, in our study, we found that MUC5AC and/or MUC6 levels were elevated in EGCs with the MSI phenotype compared to those with the MSS phenotype. This observation suggests that there may be an association between the MSI phenotype and gastric mucin expression in GCs.p53 overexpression (or mutations in the p53 gene) has been shown to play an important role in gastric carcinogenesis.[17](#ijc29916-bib-0017){ref-type="ref"}, [30](#ijc29916-bib-0030){ref-type="ref"} However, the role of p53 overexpression during the early stages of gastric carcinogenesis is not fully understood. Although the frequency of p53 overexpression in EGCs varies widely, differences in reported frequencies may be due to tumor histology, tumor grade and mucin phenotype.[16](#ijc29916-bib-0016){ref-type="ref"}, [30](#ijc29916-bib-0030){ref-type="ref"} p53 overexpression is also known to depend on the MSI status of the tumor cells; it is an uncommon genetic event in MSI‐H tumors. Therefore, our finding that p53 overexpression was a common genetic alteration in EGCs, irrespective of MSI status, was interesting. However, a recent study performed comprehensive molecular characterization of GC (TCGA).[9](#ijc29916-bib-0009){ref-type="ref"} The researchers described a molecular classification for defining the 4 major genomic subtypes of gastric cancer: EBV‐infected tumors; MSI tumors; genomically stable tumors; and chromosomally unstable tumors. In the TCGA, although p53 mutations were frequently found in chromosomally unstable tumors, which were identical to those found from chromosome instability, such mutations were rarely detected in MSI tumors.[9](#ijc29916-bib-0009){ref-type="ref"}, [33](#ijc29916-bib-0033){ref-type="ref"} In this study, p53 alterations were examined as a substitute for p53 mutations because p53 mutations are closely associated with strong nuclear p53 overexpression in GC. Whether p53 overexpression reflects mutations in the *p53* gene remains unknown; however, the *p53* gene product has been shown to be overexpressed in GC with the MSI‐high phenotype. Further studies are needed to examine this concept in greater detail.

Recent studies have shown that CRC can be clearly classified into three distinct epigenotypes (HME, IME and LME), which show correlations with *BRAF* and *KRAS* mutations, *p53* status and prognosis in patients with CRC.[23](#ijc29916-bib-0023){ref-type="ref"}, [24](#ijc29916-bib-0024){ref-type="ref"} This CIMP marker is termed a 2‐panel marker; this marker can subclassify the examined tumors into HME and non‐HME and can then divide the remaining tumors into IME and LME. In this study, HME was frequently found in EGC with the MSI‐high phenotype, and IME was closely associated with EGC with the MSS phenotype. Our results showed that the present markers reflected the epigenetic pathogenesis of RGC. From these findings, we designed our study using the CIMP marker to investigate EGC; our data support the use of the CIMP marker for evaluation of gastric carcinogenesis.

In CRC, the MSI phenotype is characterized by the accumulation of numerous mutations across the genome, mainly in microsatellite sequences, due to a defective mismatch repair system.[5](#ijc29916-bib-0005){ref-type="ref"} Both MSI‐positive advanced CRCs and precursors of MSI‐H CRCs are closely associated with *BRAF* or *KRAS* mutations and high levels of genomic methylation (CIMP‐high).[5](#ijc29916-bib-0005){ref-type="ref"}, [8](#ijc29916-bib-0008){ref-type="ref"} However, whether the same theory can be applied to EGC, which has been shown to preferentially develop into hereditary nonpolyposis colorectal cancer (HNPCC), has not been proven. In this study, *KRAS* and *BRAF* mutations, which have been frequently found in precursor lesions of MSI‐positive CRCs, were rarely detected in EGCs. In particular, no *BRAF* mutations were observed in any of the EGCs examined in this study. These findings suggest that although mutations in the *BRAF* and *KRAS* genes usually induce cell senescence in colorectal serrated lesions,[8](#ijc29916-bib-0008){ref-type="ref"} a precursor of MSI‐H cancer, tumor cells in MSI‐positive EGCs do not acquire senescence, as supported by the lack of *BRAF* and *KRAS* mutations. Thus, although MSI‐H CRCs and GCs share common molecular alterations, the molecular mechanisms of gastric carcinogenesis may be fundamentally different from colorectal carcinogenesis.

Most MSI‐H GCs also exhibit methylation of the *MLH‐1* gene as the causal epigenetic event underlying mismatch repair deficiency.[5](#ijc29916-bib-0005){ref-type="ref"}, [8](#ijc29916-bib-0008){ref-type="ref"} However, in this study, methylation of the *MLH‐1* gene was not correlated with loss or reduction of MLH‐1 expression in some of the EGCs examined. This finding suggests that only a small fraction of EGCs may have developed through mechanisms other than epigenetic alterations in the *MLH‐1* gene. Other MMR‐related factors, such as MSH‐2, MSH‐6 and PMS2, should be examined in future studies.

There is an inverse correlation between CIN status and MSI status in CRC.[4](#ijc29916-bib-0004){ref-type="ref"}, [5](#ijc29916-bib-0005){ref-type="ref"} Similarly, in GC, the genome also seems to be prone to being either high in AIs, with involvement of multiple cancer‐associated chromosome arms, or high in MSI events targeting various cancer‐associated genes. Recent studies have shown that CIN‐type alterations can be identified by genome‐wide analysis.[9](#ijc29916-bib-0009){ref-type="ref"}, [34](#ijc29916-bib-0034){ref-type="ref"} However, traditional approaches using a limited set of microsatellite markers are useful for evaluating chromosomal damage in tumor tissue specimens. In this study, although we observed a low frequency of AI‐high status in EGCs with the MSI phenotype, as shown in previous studies,[20](#ijc29916-bib-0020){ref-type="ref"}, [29](#ijc29916-bib-0029){ref-type="ref"} the frequency of AI‐high status was significantly higher in specific individual loci. However, a recent study showed that chromosomal alterations are less frequently found in GC with the MSI‐high phenotype.[9](#ijc29916-bib-0009){ref-type="ref"} Although a comprehensive analysis of chromosomal alterations was not performed in the present study, AI at cancer‐associated alleles was selectively assessed. While there may be discrepancies in the genomic changes observed between array‐based analysis and PCR‐based analysis, our data suggested that multiple chromosomal abnormalities may exist in EGCs with the MSI and MSS phenotypes, indicating that CIN may be present in EGCs having the MSI phenotype during gastric carcinogenesis.

In conclusion, we showed that the MSI phenotype in EGC was associated with older age, distinct histology and CIMP‐high status. Moreover, our data suggested that EGCs with the MSI phenotype may represent a novel type of precursor lesion in gastric carcinogenesis. The distinct histological features of EGCs with the MSI phenotype may be useful for early detection of progression to GC with the MSI phenotype. Taken together, our data supported that a detailed understanding of the mechanisms of gastric carcinogenesis in the context of the MSI‐H phenotype may facilitate prevention and effective treatment of GC.
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